Home / Health / Cancer Drug Shortage Persists, Threatening Patient Care
Cancer Drug Shortage Persists, Threatening Patient Care
11 Sep
Summary
- Academic cancer centers face ongoing drug shortages.
- Over 20% of centers report shortages of five or more drugs.
- Shortages impact treatments for major life-threatening cancers.
Cancer treatment centers across the United States continue to contend with a significant shortage of vital anti-cancer drugs. A recent survey involving over 40 academic facilities revealed that every center reported a shortage of at least one cancer therapy. Alarmingly, more than 20 percent of these facilities are currently experiencing shortages for five or more different medications.
The affected drugs are critical for treating some of the most common and deadly cancers, such as testicular, bladder, uterine, ovarian, lung, and breast cancer. Despite years of raising awareness, the situation remains critical, forcing care centers to develop and employ mitigation strategies to keep patients on their prescribed treatment plans.
These strategies often involve obtaining multiple authorizations from health insurance companies, which adds considerable time and potential delays to patient care. To combat these shortages, proposed solutions include updating federal drug production policies, incentivizing domestic drug manufacturing, and developing new cancer vaccines. Although legislation has been introduced, it has yet to pass.
The implications of these ongoing shortages are profound, placing additional stress on an already burdened healthcare system and diverting attention from essential treatment and clinical trials. Efforts to alleviate the crisis are reportedly underway, but the impact on patient care persists.
